Compare · MGRX vs SHC
MGRX vs SHC
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Sotera Health Company (SHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and SHC operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- SHC is the larger of the two at $5.21B, about 627.6x MGRX ($8.3M).
- Over the past year, MGRX is down 81.7% and SHC is up 13.0% - SHC leads by 94.7 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- SHC has more recent analyst coverage (25 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Sotera Health Company
- Price
- $0.39-4.82%
- $18.21-0.27%
- Market cap
- $8.3M
- $5.21B
- 1M return
- -27.70%
- -3.63%
- 1Y return
- -81.74%
- +12.97%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 1
- 1
- Recent ratings
- 0
- 25
Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form 425 filed by Mangoceuticals Inc.
- Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
- Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
- SEC Form 425 filed by Mangoceuticals Inc.
Latest SHC
- Executive Chairman Petras Michael B. Jr. sold $21,174,786 worth of shares (1,144,515 units at $18.50), decreasing direct ownership by 43% to 397,912 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Leadership Update
- President of Sterigenics Rutz Michael P sold $2,825,250 worth of shares (150,000 units at $18.84), decreasing direct ownership by 31% to 334,279 units (SEC Form 4)
- Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,316 shares, decreasing direct ownership by 5% to 217,304 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by Sotera Health Company
- SEC Form 10-Q filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
- Sotera Health Announces Second-Quarter 2026 Earnings Release Date